Key terms
About PIRS
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PIRS news
Yesterday
8:29am ET
Pieris Pharmaceuticals sees cash runway into 2027
Yesterday
8:27am ET
Pieris Pharmaceuticals to discontinue all R&D efforts, reduce workforce, board
Mar 21
11:18am ET
Biotech Alert: Searches spiking for these stocks today
Mar 20
11:06am ET
Biotech Alert: Searches spiking for these stocks today
Jan 24
8:07am ET
Soleno Therapeutics announces appointments to its leadership team
No recent news articles are available for PIRS
PIRS Financials
Key terms
Ad Feedback
PIRS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PIRS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range